A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

2024-516369-36-00 Protocol 2020-306-GLOB1 Human pharmacology (Phase I) - Other Ended

Start 9 Feb 2021 · End 16 Jan 2025 · Status Ended · 1 EU/EEA countries · 8 sites · Protocol 2020-306-GLOB1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 46
Countries 1
Sites 8

- Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

Key facts

Sponsor
Hutchmed Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Feb 2021 → 16 Jan 2025
Decision date (initial)
2024-08-21
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516369-36-00
EudraCT number
2020-003751-15

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

- Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

VersionLevelCodeTermSystem organ class
21.0 LLT 10000886 Acute myeloid leukemia 10029104
20.0 PT 10077465 Myeloproliferative neoplasm 100000004864
20.0 HLT 10002450 Angioimmunoblastic T-cell lymphomas 10029104
21.1 PT 10066476 Haematological malignancy 100000004864
27.0 PT 10028533 Myelodysplastic syndrome 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hutchmed Ltd.

Sponsor organisation
Hutchmed Ltd.
Address
Building 4, 720 Cailun Road, China (Shanghai) Pilot Free Trade Zone 720 Cailun Road China (Shanghai) Pilot Free Trade Zone
City
Shanghai
Postcode
201203
Country
China

Scientific contact point

Organisation
Hutchmed Ltd.
Contact name
William Schelman

Public contact point

Organisation
Hutchmed Ltd.
Contact name
William Schelman

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 37 8
Rest of world
United States
9

Investigational sites

Spain

8 sites · Ended
Institut Catala D'oncologia
Hemtaology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitario 12 De Octubre
Hemtaology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitari Vall D Hebron
Hematology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Y Politecnico La Fe
Hematology, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Hospital Clinico Universitario De Valencia
Hematology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Fundacion Jimenez Diaz
Hematology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario De Salamanca
Hematology, Paseo De San Vicente 58-182, 37007, Salamanca
Clinica Universidad De Navarra
Hematology, Pio XII Etorbidea 36, 31008, Pamplona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-02-09 2021-04-12 2024-04-16

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-14 Spain Acceptable with conditions
2024-08-21
2024-08-21